Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma have?
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma has 250 citations in the OpenAlex counts ScholarIQ stores.
When was Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma published?
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma has 2023 year in the ScholarIQ index.
What is the open-access status of Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma?
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma has green oa status in the ScholarIQ index.
What is the DOI of Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma?
The DOI for Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma is on the source record.
What is the PMID of Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma?
The PMID for Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma is on the source record.
What is the OpenAlex record for Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma?
The OpenAlex for Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma is on the source record.